Preparation, characterization, and antitumor activity of new ethylenediamine platinum(IV) complexes containing mixed carboxylate ligands

Khokhar, Abdul R.; Deng, Yuanjian; Kido, Yuichiro; Siddik, Zahid H.

doi:10.1016/0162-0134(93)80015-2

Cited by 48 publications

(30 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For a series of different Pt(IV) complexes which, upon reduction, yield the same Pt(II) species there was an 800-fold range in cytotoxicity [13]. Although the pharmacology of Pt(IV) compounds seems to depend strongly on the nature of the axial ligands, activity can be also influenced by the potency of the Pt(II) complex formed upon reduction [14].…”

Section: Platinummentioning

confidence: 99%

Redox activation of metal-based prodrugs as a strategy for drug delivery

Graf

Lippard

2012

Advanced Drug Delivery Reviews

471

335

View full text Add to dashboard Cite

This review provides an overview of metal-based anticancer drugs and drug candidates. In particular, we focus on metal complexes that can be activated in the reducing environment of cancer cells, thus serving as prodrugs. There are many reports of Pt and Ru complexes as redox-activatable drug candidates, but other d-block elements with variable oxidation states have a similar potential to serve as prodrugs in this manner. In this context are compounds based on Fe, Co, or Cu chemistry, which are also covered. A trend in the field of medicinal inorganic chemistry has been toward molecularly targeted, metal-based drugs obtained by functionalizing complexes with biologically active ligands. Another recent activity is the use of nanomaterials for drug delivery, exploiting passive targeting of tumors with nanosized constructs made from Au, Fe, carbon, or organic polymers. Although complexes of all of the above mentioned metals will be described, this review focuses primarily on Pt compounds, including constructs containing nanomaterials.

show abstract

Section: Platinummentioning

confidence: 99%

Redox activation of metal-based prodrugs as a strategy for drug delivery

Graf

Lippard

2012

Advanced Drug Delivery Reviews

471

335

View full text Add to dashboard Cite

show abstract

“…Despite some contradictory results (Khokhar et al, 1993;Talman et al, 1998), it is now widely accepted that the antitumor activity of Pt(IV) complexes is due to their reduction to Pt(II) analogues. It was experimentally observed that DNAbinding activity of Pt(IV) complexes is increased in presence of some intracellular reductants (Choi et al, 1998), and Pt(IV) complexes are reduced by various biomolecules present in blood and cells.…”

Section: Platinum(iv) Complexesmentioning

confidence: 99%

Coordination compounds in cancer: Past, present and perspectives

Trudu¹,

Amato

Vaňhara³

et al. 2015

J Appl Biomed

136

View full text Add to dashboard Cite

“…It may be sheer luck that iproplatin was selected by Tobe and co-workers based on its high solubility rather than cytotoxicity screening, and it is possible that a number of potential candidates have been passed up based on poor in vitro performance. For example, Siddik and co-workers [32] examined a series of platinum(IV) complexes and selected a number for further development based on their IC 50 values. Those selected contained axial trifluoroacetato ligands, with high reduction potentials (i.e.…”

Section: Cytotoxicitymentioning

confidence: 99%